RNS Number : 7851Z
ValiRx PLC
18 September 2025

ValiRx PLC
("ValiRx" or the **"Company")**

Inaphaea Commercial Update

London, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, is pleased to provide the following updates on its wholly owned subsidiary Inaphaea Limited (**"Inaphaea"**).

Inaphaea is pleased to announce that, as it continues to expand its capability partnerships, it has signed a Collaboration Agreement with Swiss techbio company, TwinEdge Bioscience (**"TwinEdge"**). TwinEdge combine cutting-edge computational biology, artificial intelligence, and personalized medicine to transform how new cancer therapies are developed. Under the agreement, TwinEdge will combine their proprietary methodology with drug response datasets obtained from Inaphaea's Patient derived Cells (PDCs) to create "patient avatars" which are digitally actionable representations of the patients' tumours, ready for testing with new drugs in "in-avatar" trials. This AI aided classification of responses in PDCs can be used to provide mechanistic insight, predict response of new, or repurposed, drugs and identify biomarkers for patient selection in-silico in what will be one of the world's largest population of digital twins created by TwinEdge.

As part of its continued service and product development, Inaphaea has also signed a Material Transfer Agreement with Nottingham University Hospitals NHS Trust to obtain new PDC models, prioritising ovarian, breast, lung and prostate cancer samples with matched blood plasma, white blood cells and ascites/pleural fluids with full ethics and commercial use consent. These prospectively collected samples, with associated clinical data, will be used in advanced 3D models to understand host immune engagement, for example with CytoLytix oncolytic peptide program, as well as external client projects.

Additionally, a series of 6 colorectal Cancer PDC models have also been transferred to Cellomatics Ltd under the Evaluation Use Agreement, announced on 30 April 2025, in parallel with characterisation by low pass sequencing underway at Inaphaea.

Inaphaea is also pleased to announce that its collaborative 3K Screen program with Dominion, announced on 12 May 2025, has identified around 250 hits from the initial screen against 5 different models. Around 50 of these molecules, included as controls to validate the approach, have known activity in cancer. Inaphaea and Dominion have reviewed the initial hits and prioritised them based on selection criteria including oral availability of the drugs, freedom to operate regarding current patent position and likely patient positioning for unmet clinical need. A top 10 set of molecules has been selected for inclusion in the next phase which included testing of full dose response curves in selected Patient Derived Models at Inaphaea and Dominion. The data generated will be processed in TwinEdge's digital twin AI platform to support new patent filings and initial commercial discussions with potential licensees as well as application for non-dilutive grant funding to support further development of these and other assets from the 3K screen. Sales and marketing for PredictRx personalised therapy selection has also been initiated by Dominion with initial sales anticipated in Q4.

Mark Eccleston, CEO of ValiRx commented *"Our new partnership with TwinEdge Bioscience is a huge step forward in both our service and in house development capabilities at Inaphaea and for the broader ValiRx group. Digitising our 2D and 3D PDC models further leverages the valuable RNA-seq and treatment response data sets we have and provides another New Approach Methodology (NAM) to accelerate our translational drug development programs. The Patient Avatar approach enables unprecedented large-scale clinical insight at translational and early clinical decision points allowing an in-silico screen of 10,000 digitised patents and counting. This approach will accelerate internal and customer drug development programs and provide clinical insight at a fraction of the cost of a real-world clinical trial. The predictive biomarker readouts will also streamline future in-human and in-canine clinical trials by matching the right patient with the right drug, increasing the chances of success and maximising asset value to prospective licensees through an expedited clinical trails pathway."*

"We are also pleased that the additional quality control work and data generation through low pass sequencing is being recognised with colorectal cancer PDCs now under evaluation with Cellomatics. The new prospective sample collection capability established with the local NHS trust will support ongoing PDC development and supply agreements whilst also expanding our capabilities in the immune oncology space through the ability to procure patient blood samples matched to the PDC models. This is a major advantage for both our internal programs such as Cytolytix, especially when combined with advanced model platforms through our collaborations with ScreenIn3d and VoxCell, as well as for service provision to clients. Our Internal programmes will also provide excellent case studies to support further client project procurement."

"Finally, building on our commitment to realise the potential of the assets within Inaphaea, we are also very excited to announce the selection of the top 10 prioritised candidates from our 3k-screen collaboration with Dominion. We will be developing a data package for these assets based on PDC profiling, initially in Ovarian cancer, and our new in-silico clinical prediction and precision biomarker approach for patient selection with TwinEdge providing a virtual clinical trial data set to take forward into partnering discussions whilst actively applying for grant funding to continue their development. We're also working with Dominion to support outreach and promotion of the PredictRx platform with early revenue anticipated as soon as Q4 2025."

Michael Prosser, CEO of TwinEdge Commented *"This partnership with ValiRx and Inaphaea marks a significant milestone, both for TwinEdge Bioscience as a company, and for the broader deployment of New Approach Methodologies (NAMs) in oncology drug development. Together, we are combining deep scientific expertise with complementary innovative platforms to generate more predictive insights, reduce reliance on animal models, and*

ultimately accelerate better therapies to patients. At TwinEdge we are proud to be at the forefront of Digital Twin technology, and by delivering population-scale insight throughout the drug development process, we enable our clients to make better decisions regarding which translational programmes progress to clinical trials, and how those clinical trials are designed and run. We aim to redefine translational models, speed decision-making, and support the development of next-generation oncology treatments. Through partners such as ValiRx and Inaphaea, we can help translate science into real patient outcomes."

Anthony Holmes, CEO of Dominion commented "*We're delighted with the progress of our collaboration with Inaphaea on the 3K Screen programme. The identification of around 250 potential hits from this comprehensive drug repositioning screen represents a significant milestone in our joint efforts to unlock new cancer treatment opportunities from existing approved drugs. The selection of our top 10 priority candidates for advanced testing demonstrates the quality and commercial potential within this dataset. This collaboration perfectly complements our PredictRx personalised therapy platform, which we're excited to bring to market. By combining Inaphaea's extensive biobank with our analytical capabilities and fresh sample collection expertise, we're creating a powerful pipeline of both repositioned drugs and personalised treatment solutions that could significantly benefit cancer patients while generating value for pharmaceutical partners."*

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company take responsibility for this announcement.

*** ENDS ***

Engage with the ValiRx management team directly by asking questions, watching video summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor hub here: https://valirx.com/s/cc8ef3

For more information, please contact:

Investor questions on this announcement We encourage all investors to share questions on this announcement via our investor hub	https://valirx.com/link/yaG96r
ValiRx plc Dr Mark Eccleston, CEO	**Tel: +44 115 784 0026** www.valirx.com Mark.Eccleston@valirx.com
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Ludovico Lazzaretti	**Tel: +44 (0) 20 7213 0880**
Shard Capital Partners LLP (Sole Broker) Damon Heath	**Tel: +44 (0) 20 7186 9000**
V Formation (Public Relations) Lucy Wharton - Senior PR Executive Sue Carr - Director	**+44 (0) 115 787 0206** www.vformation.biz lucy@vformation.biz sue@vformation.biz

Subscribe to our news alert service: https://valirx.com/s/f298d1

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary

Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

UPDDGGDCSGBDGUR